Article
Key Tailwinds and Headwinds Impacting the Major Developed Markets
IQVIA Market Prognosis
May 16, 2023
Download

This article reviews the latest pharmaceutical forecasts from IQVIA's Market Prognosis and presents an overview of key tailwinds and headwinds impacting the eight major developed pharmaceutical markets over the next five years. The analysis is based on findings from Canada, France, Germany, Italy, Japan, Spain, UK and the USA, which are covered in IQVIA's Market Prognosis edition published in March 2023.

In the aftermath of the COVID-19 pandemic and under the impact of increased pressure on healthcare budgets, ongoing economic challenges and stretched healthcare systems, pharmaceutical sales growth in the combined eight major developed markets is forecast to slow to a compound annual growth rate (CAGR) of 4.9% over 2022–2027, from 6.1% over 2017–2022. Of the eight markets, seven are forecasted to post CAGRs of around 5-6% (in constant dollar terms), while Japan, the second largest market in the group, is projected to contract by -0.1% over the 2022–2027 period. Italy is the only market where growth in 2022–2027 period is forecast to be faster than over 2017–2022.

To learn about the key tailwinds and headwinds that are impacting the Major Developed Markets, please download the article.

Related solutions

Contact Us